Txmd price target
WebMar 22, 2024 · IDEX stock analysis year-to-date. IDEX stock hit a 2024 high of $1.44 in early January and a low of $0.87 later in the same month. In 2024 its stock price ranged from 88 cents to $5.53. In an interview with Capital.com, Vinod Jain, senior analyst at Aite-Novarica Group, said “the stock could see more volatility due to its current price point”. WebView real-time TXMD stock price and news, ... Average price target from 1 ratings: $5.00. Average score: Sell. Under. ... Futures prices are delayed at least 10 minutes as per exchange requirements.
Txmd price target
Did you know?
WebPrice target. 5.00 0.00 0.00%. The 1 analyst offering 1 year price forecasts for TXMD have a max estimate of — and a min estimate of —. Analyst rating. Based on 1 analyst giving stock ratings to TXMD in the past 3 months. EPS. Annual Quarterly More WebThe median TXMD price target (a different metric than the average or mean) was $5.0 as of 2024-04-04, the highest TXMD price target in the range was $5.0 while the lowest TXMD price target in the range was $5.0, with a standard deviation of $0.0. Get the latest Zacks research report on TXMD — FREE. 10 ETFs With Most Upside To Analyst Targets
WebTherapeuticsMD, Inc. Common Stock (TXMD) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. WebTXMD Complete TherapeuticsMD Inc. stock news by MarketWatch. ... TherapeuticsMD started at overweight with $11 stock price target at J.P. Morgan. Jun. 15, 2024 at 7:44 …
WebNumber of Analysts. 3. Standard Deviation. 1.154. Look at TherapeuticsMD's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential. Look at the analyst's track record to determine if they have a history of accurately predicting stock prices. WebWith Protalix Biotherapeutics stock trading at $2.10 per share, the total value of Protalix Biotherapeutics stock (market capitalization) is $120.44M. Protalix Biotherapeutics stock was originally listed at a price of $850.00 in May 15, 1998. If you had invested in Protalix Biotherapeutics stock at $850.00, your return over the last 24 years ...
WebApr 12, 2024 · These shares were sold in multiple transactions at prices of $3.63 through $3.71, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each …
WebFind the latest TherapeuticsMD Inc (TXMD) stock forecast, 12-month price target, predictions and analyst recommendations. dr jesus lucasWebTXMD updated stock price target summary. Dow Jones, a News Corp company About WSJ. News Corp is a global, ... Futures prices are delayed at least 10 minutes as per exchange … dr. jesus manuel roman velezWebApr 12, 2024 · The 52 Week Price Change displays the percentage price change over the most recently completed 52 weeks (260 trading days). This is a longer-term price change metric. The 52 week price change is a ... dr jesus mantecaWebApr 7, 2024 · TXMD Price Targets by Month Average Share Price and Price Target by Month Chart Description. The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual … dr jesus martinez materno fetalWebJul 31, 2024 · Knight receives license to TX-004HR and TX-001HR and agrees to invest $20 million in TherapeuticsMD MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)--Jul. 31, 2024-- Knight Therapeutics Inc. (TSX: GUD) (“Knight”),a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare … dr jesus machadoWeb1 day ago · Price To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for TherapeuticsMD (TXMD) dr jesusmarWebApr 14, 2024 · Credit Suisse Group lifted their price target on First Solar from $152.00 to $163.00 and gave the company a neutral rating in a report on Wednesday, March 15th. Finally, Susquehanna lifted their price target on First Solar from $175.00 to $225.00 and gave the company a positive rating in a report on Wednesday, January 18th. dr. jesus maria garza cantu